Eletriptan contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Eletriptan}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERI...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
RELPAX is contraindicated in patients with: | |||
* Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1)]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c | publisher = | date = | accessdate = }}</ref> | * Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)]. | ||
* History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)]. | |||
* Peripheral vascular disease [see Warnings and Precautions (5.5)]. | |||
* Ischemic bowel disease [see Warnings and Precautions (5.5)]. | |||
* Uncontrolled hypertension [see Warnings and Precautions (5.8)]. | |||
* Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine1 (5-HT1) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1)]. | |||
* Hypersensitivity to RELPAX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)]. | |||
* Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 07:47, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
RELPAX is contraindicated in patients with:
- Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1)].
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)].
- History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)].
- Peripheral vascular disease [see Warnings and Precautions (5.5)].
- Ischemic bowel disease [see Warnings and Precautions (5.5)].
- Uncontrolled hypertension [see Warnings and Precautions (5.8)].
- Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine1 (5-HT1) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1)].
- Hypersensitivity to RELPAX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].
- Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].[1]
References
Adapted from the FDA Package Insert.